Sight Sciences FY2024 EPS Estimate Raised by William Blair

Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) - William Blair raised their FY2024 earnings per share estimates for Sight Sciences in a research note issued on Monday, November 11th. William Blair analyst M. Andrew now expects that the company will post earnings per share of ($1.10) for the year, up from their prior estimate of ($1.19). The consensus estimate for Sight Sciences' current full-year earnings is ($1.01) per share. William Blair also issued estimates for Sight Sciences' Q4 2024 earnings at ($0.31) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.29) EPS and FY2025 earnings at ($1.08) EPS.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $20.16 million during the quarter, compared to analyst estimates of $20.41 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%.

A number of other research firms also recently issued reports on SGHT. Lake Street Capital lowered shares of Sight Sciences from a "buy" rating to a "hold" rating and decreased their price target for the company from $10.00 to $5.00 in a report on Monday, November 4th. Piper Sandler restated a "neutral" rating and issued a $5.50 target price (down from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a report on Friday, November 8th. Finally, Morgan Stanley cut their price target on Sight Sciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a report on Monday. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $5.50.

Sight Sciences Stock Down 5.9 %

Sight Sciences stock traded down $0.25 during mid-day trading on Wednesday, reaching $3.98. The company's stock had a trading volume of 255,615 shares, compared to its average volume of 199,478. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.50 and a current ratio of 10.18. Sight Sciences has a twelve month low of $1.80 and a twelve month high of $8.45. The business has a 50 day moving average price of $5.85 and a 200-day moving average price of $6.24.

Insiders Place Their Bets

In other news, insider Jeremy B. Hayden sold 4,878 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $6.08, for a total value of $29,658.24. Following the completion of the transaction, the insider now owns 158,687 shares of the company's stock, valued at approximately $964,816.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Sight Sciences news, insider Jeremy B. Hayden sold 4,878 shares of the company's stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $6.08, for a total value of $29,658.24. Following the completion of the sale, the insider now directly owns 158,687 shares in the company, valued at $964,816.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Matthew Link sold 21,831 shares of Sight Sciences stock in a transaction on Monday, October 21st. The shares were sold at an average price of $5.61, for a total value of $122,471.91. Following the transaction, the insider now owns 663,550 shares in the company, valued at approximately $3,722,515.50. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 97,357 shares of company stock worth $574,666. Insiders own 28.90% of the company's stock.

Institutional Investors Weigh In On Sight Sciences

Institutional investors and hedge funds have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System acquired a new stake in shares of Sight Sciences during the first quarter worth $59,000. Steele Capital Management Inc. purchased a new position in Sight Sciences in the 2nd quarter worth about $67,000. SG Americas Securities LLC acquired a new stake in Sight Sciences during the 3rd quarter worth about $75,000. The Manufacturers Life Insurance Company purchased a new stake in Sight Sciences during the second quarter valued at about $95,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Sight Sciences in the third quarter worth about $136,000. Institutional investors and hedge funds own 55.51% of the company's stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.